JP2005528336A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005528336A5 JP2005528336A5 JP2003556441A JP2003556441A JP2005528336A5 JP 2005528336 A5 JP2005528336 A5 JP 2005528336A5 JP 2003556441 A JP2003556441 A JP 2003556441A JP 2003556441 A JP2003556441 A JP 2003556441A JP 2005528336 A5 JP2005528336 A5 JP 2005528336A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- polypeptide
- disease
- acid molecule
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims description 41
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 40
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 40
- 150000007523 nucleic acids Chemical class 0.000 claims description 29
- 108020004707 nucleic acids Proteins 0.000 claims description 28
- 102000039446 nucleic acids Human genes 0.000 claims description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 23
- 201000010099 disease Diseases 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 15
- 239000000523 sample Substances 0.000 claims description 9
- 102000004127 Cytokines Human genes 0.000 claims description 8
- 108090000695 Cytokines Proteins 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 5
- 238000003745 diagnosis Methods 0.000 claims description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 3
- 230000001363 autoimmune Effects 0.000 claims description 3
- 230000009547 development abnormality Effects 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- 239000002853 nucleic acid probe Substances 0.000 claims description 3
- 230000001575 pathological effect Effects 0.000 claims description 3
- 230000002062 proliferating effect Effects 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 208000012902 Nervous system disease Diseases 0.000 claims description 2
- 208000025966 Neurological disease Diseases 0.000 claims description 2
- 230000003321 amplification Effects 0.000 claims description 2
- 239000012472 biological sample Substances 0.000 claims description 2
- 230000006371 metabolic abnormality Effects 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 5
- 239000013068 control sample Substances 0.000 claims 3
- 241001465754 Metazoa Species 0.000 claims 2
- 238000009739 binding Methods 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 238000012544 monitoring process Methods 0.000 claims 2
- 239000013610 patient sample Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000009261 transgenic effect Effects 0.000 claims 2
- 208000031295 Animal disease Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 description 5
- 230000005856 abnormality Effects 0.000 description 5
- 230000004853 protein function Effects 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000001915 proofreading effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0130738.8A GB0130738D0 (en) | 2001-12-21 | 2001-12-21 | Protein |
| PCT/GB2002/005865 WO2003055911A2 (en) | 2001-12-21 | 2002-12-20 | Cystine-knot fold protein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005528336A JP2005528336A (ja) | 2005-09-22 |
| JP2005528336A5 true JP2005528336A5 (https=) | 2006-02-16 |
Family
ID=9928236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003556441A Pending JP2005528336A (ja) | 2001-12-21 | 2002-12-20 | シスチン−ノットフォールドタンパク質 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7619065B2 (https=) |
| EP (1) | EP1463754B1 (https=) |
| JP (1) | JP2005528336A (https=) |
| KR (1) | KR20040089093A (https=) |
| CN (1) | CN1620466A (https=) |
| AT (1) | ATE397624T1 (https=) |
| AU (1) | AU2002353207B2 (https=) |
| CA (1) | CA2470781A1 (https=) |
| DE (1) | DE60227002D1 (https=) |
| EA (1) | EA007611B1 (https=) |
| ES (1) | ES2306802T3 (https=) |
| GB (1) | GB0130738D0 (https=) |
| IL (2) | IL162592A0 (https=) |
| MX (1) | MXPA04006062A (https=) |
| WO (1) | WO2003055911A2 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0130738D0 (en) | 2001-12-21 | 2002-02-06 | Serono Internat S A | Protein |
| US7193069B2 (en) | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
| US9045553B2 (en) | 2004-05-27 | 2015-06-02 | Acceleron Pharma, Inc. | Cerberus/Coco derivatives and uses thereof |
| JP2008500373A (ja) | 2004-05-27 | 2008-01-10 | アクセルロン ファーマ インコーポレーテッド | ケルベロス（Ｃｅｒｂｅｒｕｓ）／ココ（Ｃｏｃｏ）誘導体およびそれらの使用 |
| CA2657683A1 (en) * | 2006-01-12 | 2007-07-19 | Mark Douglas Davies | Cystine-knot fold cytokine |
| CA2671983A1 (en) | 2006-12-08 | 2009-06-19 | Acceleron Pharma Inc. | Uses of cerberus, coco and derivatives thereof |
| EP2393917B1 (en) | 2009-02-03 | 2016-04-06 | Koninklijke Nederlandse Akademie van Wetenschappen | Culture medium for epithelial stem cells and organoids comprising said stem cells. |
| EP2412800A1 (en) | 2010-07-29 | 2012-02-01 | Koninklijke Nederlandse Akademie van Wetenschappen | Liver organoid, uses thereof and culture method for obtaining them |
| US9752124B2 (en) | 2009-02-03 | 2017-09-05 | Koninklijke Nederlandse Akademie Van Wetenschappen | Culture medium for epithelial stem cells and organoids comprising the stem cells |
| TWI799366B (zh) | 2015-09-15 | 2023-04-21 | 美商建南德克公司 | 胱胺酸結骨架平臺 |
| US10961305B2 (en) | 2016-12-21 | 2021-03-30 | Mereo Biopharma 3 Limited | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
| GB201721615D0 (en) | 2017-12-21 | 2018-02-07 | Koninklijke Nederlandse Akademie Van Wetenschappen | Immune cell organoid co-cultures |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0130738D0 (en) | 2001-12-21 | 2002-02-06 | Serono Internat S A | Protein |
| US7193069B2 (en) * | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
-
2001
- 2001-12-21 GB GBGB0130738.8A patent/GB0130738D0/en not_active Ceased
-
2002
- 2002-12-20 JP JP2003556441A patent/JP2005528336A/ja active Pending
- 2002-12-20 EA EA200400813A patent/EA007611B1/ru not_active IP Right Cessation
- 2002-12-20 CN CNA028282744A patent/CN1620466A/zh active Pending
- 2002-12-20 MX MXPA04006062A patent/MXPA04006062A/es not_active Application Discontinuation
- 2002-12-20 EP EP02788225A patent/EP1463754B1/en not_active Expired - Lifetime
- 2002-12-20 IL IL16259202A patent/IL162592A0/xx unknown
- 2002-12-20 AU AU2002353207A patent/AU2002353207B2/en not_active Ceased
- 2002-12-20 KR KR10-2004-7009759A patent/KR20040089093A/ko not_active Ceased
- 2002-12-20 ES ES02788225T patent/ES2306802T3/es not_active Expired - Lifetime
- 2002-12-20 AT AT02788225T patent/ATE397624T1/de not_active IP Right Cessation
- 2002-12-20 WO PCT/GB2002/005865 patent/WO2003055911A2/en not_active Ceased
- 2002-12-20 DE DE60227002T patent/DE60227002D1/de not_active Expired - Lifetime
- 2002-12-20 CA CA002470781A patent/CA2470781A1/en not_active Abandoned
-
2004
- 2004-06-17 IL IL162592A patent/IL162592A/en not_active IP Right Cessation
- 2004-06-21 US US10/872,898 patent/US7619065B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2798090B1 (en) | Nucleic acid analysis using emulsion pcr | |
| KR20100016525A (ko) | 녹내장 진행 리스크의 판정 방법 | |
| CA2485968A1 (en) | Method for predicting autoimmune diseases | |
| JP2004511236A (ja) | 核酸差異を含有するポリヌクレオチドを同定かつ単離する方法 | |
| KR101953176B1 (ko) | 미처리 혈액을 사용한 ｐｃｒ 및 ｈｌａ 타이핑 방법 | |
| RU2014123511A (ru) | Способы лечения, диагностики и мониторинга болезни альцгеймера | |
| AU2016361646B2 (en) | Method for assessing the risk of complications in patients with systemic inflammatory response syndrome (SIRS) | |
| JP2005528336A5 (https=) | ||
| Yamate et al. | Analysis of osteopontin DNA in patients with urolithiasis | |
| CN104450727A (zh) | X-连锁低磷酸盐血症性佝偻病的致病基因及其编码蛋白质和应用 | |
| US20030175755A1 (en) | Method of collecting data for estimation of susceptibility to periodontal disease | |
| JP6113159B2 (ja) | ナチュラルキラー細胞を同定するエピジェネティックマーカー | |
| JP2002526124A (ja) | 変異型ｇｐｉｉｉａ対立遺伝子および／または変異型ｇｐｉｉｂ対立遺伝子の存在を決定することにより、神経系疾患のリスクを有する対象を治療又は同定する方法 | |
| CN112501286A (zh) | 一种遗传性甲状腺功能异常性疾病致病基因的标志物及其检测试剂盒 | |
| KR102280463B1 (ko) | 백혈병 진단용 프라이머 세트 및 이를 이용한 백혈병 진단 방법 | |
| JP5301281B2 (ja) | 臓器特異的遺伝子、その同定方法およびその用途 | |
| CA2525179A1 (en) | A gene equation to diagnose rheumatoid arthritis | |
| CN111383711B (zh) | 一种肿瘤突变负荷的检测试剂盒及其检测方法和装置 | |
| JP6494356B2 (ja) | 非アルコール性脂肪性肝疾患及び／又は非アルコール性脂肪肝炎の発症リスク及び／又は重症化リスクの判定方法、並びに該判定用オリゴヌクレオチドキット | |
| EP1501949A2 (en) | Ssh based methods for identifying and isolating unique nucleic acid sequences | |
| JP2005137202A (ja) | 多発性骨髄腫の分子診断方法 | |
| JP4889258B2 (ja) | ウシ白血病発症に対する抵抗性の判定方法 | |
| JP4445611B2 (ja) | 反復配列の多型分析用装置 | |
| CN111440783B (zh) | 一种caii的突变体及其应用 | |
| JP7791565B2 (ja) | プードル種の筋ジストロフィーを検査する方法 |